Agentes antiplaquetarios para la claudicación intermitente
Información
- DOI:
- https://doi.org/10.1002/14651858.CD001272.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 09 noviembre 2011see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Vascular
- Copyright:
-
- Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Peng Wong (PW): selected trials, extracted data, assessed risk of bias, analysed and interpreted the data, and drafted manuscript.
Lee‐Yee Chong (LYC): selected trials, extracted data, assessed risk of bias,analysed and interpreted the data, and drafted manuscript.
Dimitri Mikhailidis (DM): provided advice on antiplatelets and appraised the manuscript.
Peter Robless (PR): interpreted the data, appraised the manuscript.
Gerard Stansby (GS): resolved disagreements on inclusion, interpreted the data, drafted and appraised the manuscript.
Sources of support
Internal sources
-
No sources of support supplied
External sources
-
Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK.
Declarations of interest
DM: "I have attended meetings and advisory boards and given some lectures sponsored by Merck, Sharp and Dohme (MSD) and Genzyme. I am editor‐in‐chief of several journals. Hence some royalties are paid to me (Bentham publications, SAGE publications and Informa publications)."
Acknowledgements
A protocol and draft review of this topic was originally written by a team led by Dr David Moher. The authors would like to thank the personnel from Cochrane Peripheral Vascular Diseases Review group, especially Marlene Stewart and Karen Welch for their invaluable assistance and advice.
Version history
| Published | Title | Stage | Authors | Version |
| 2011 Nov 09 | Antiplatelet agents for intermittent claudication | Review | Peng F Wong, Lee Yee Chong, Dimitris P Mikhailidis, Peter Robless, Gerard Stansby | |
| 2003 Oct 20 | Antiplatelet agents for intermittent claudication | Protocol | Peter Robless, Dimitris P Mikhailidis, Gerard P Stansby | |
Differences between protocol and review
The interpretation of the types of participants, the interventions and outcomes as described in protocol of this review (Robless 2003) were in some instances unclear and the reviewers have therefore provided clarification by providing definitions of patients with PAD, antiplatelet agents and cardiovascular events and adverse events.
The initial published protocol proposed to perform analysis on quality of life (QoL) and cost effectiveness. However, none of the studies included in this review reported these data, and it was not possible to perform these analyses. The types of studies included in the review were narrowed down compared with the protocol by excluding quasi‐randomised and cross‐over trials to reduce the risk of biases from non‐random sequence generation and difficulty in attributing the events to the intervention in question, respectively. The required length of the intervention was increased from 4 weeks to 3 months in order to reduce the potential of bias from under‐reporting from a short period of treatment, and also to allow real assessment of antiplatelet agents and their longer term impact on mortality.
The assessment of the methodological quality of the included studies was changed to the updated Cochrane Collaboration's recommended 'Risk of bias' tool (Higgins 2011a).
Notes
August 2003: A protocol on this topic was originally published in Issue 1, 1999 of The Cochrane Library by Professor David Moher and his team. Mr Peter Robless and colleagues have taken over the review.
